Eli Lilly's Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires.
Eli Lilly & Co (LLY)
Market is closed
News
- 1 - 10
- Next >>
Goldman Sachs Maintained a Buy Rating on Eli Lilly (LLY), Kept the PT Unchanged
Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for High Returns. On July 31, Asad Haider of Goldman Sachs maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price...
11 Best Stocks to Invest in for High Returns
On August 4, Tom Lee, co-founder and managing partner of Fundstrat Capital, and chairman of BitMine, joined CNBC Television to discuss the markets and the state of the economy.
Eli Lilly and Co (LLY) Traded Lower in Q2 Despite Good Results
Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here.
12 Most Profitable Growth Stocks to Buy According to Billionaires
On July 28, Peter Boockvar, CIO at One Point BFG Wealth Partners, joined Worldwide Exchange on CNBC to warn that high tariffs, weak earnings beyond tech, and inflated valuations may limit market upside...
Eli Lilly (LLY) Partners with LTZ to Develop Myeloid Engager Therapies
Eli Lilly & Company (NYSE:LLY) is one of the top 10 medical AI companies to buy according to analysts.
Top 10 Medical AI Companies to Buy According to Analysts
Artificial intelligence is transforming medical sciences in ways not seen before.
15 Stocks in Jim Cramer’s Game Plan for This Week
On Friday’s episode of Mad Money, host Jim Cramer shared his thoughts on another intense week during earnings season as he turned his attention to several known companies that would be reporting their...
Eli Lilly and Company (LLY) Slid Despite Strong Top-Line Growth
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q2 2025 investor letter.
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer
Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date.
- 1 - 10
- Next >>
Billionaire Hedge Funds
